---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125523"
form_type: "8-K"
ticker: "SYBX"
cik: "0001527599"
company_name: "SYNLOGIC, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:50:22.810305+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Synlogic posts Q3 net loss of $0.1M, cash $19.4M; evaluating strategic options

## Summary
- Net loss of $0.1M ($0.01 per share) vs $12.1M ($2.57 loss per share) in Q3 2023.
- Cash and cash equivalents of $19.4M as of Sep 30, 2024; no revenue for Q3.
- R&D expenses show $0.7M benefit due to clinical trial refund and accrual reversal.
- Restructuring charges of $0.3M related to workforce reduction from Synpheny-3 discontinuation.
- Retained Lucid Capital Markets to explore strategic alternatives including M&A or business combination.

## SEC filing metadata
- accession: 0000950170-24-125523
- form_type: 8-K
- ticker: SYBX
- cik: 0001527599
- company_name: SYNLOGIC, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527599/000095017024125523/0000950170-24-125523-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527599/000095017024125523/sybx-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125523
- JSON: https://secwatch.observer/filing/0000950170-24-125523.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125523.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.